August 24, 2016 (Ft. Lauderdale, Florida)
In the ostomy patient, the surgical procedure, which includes substantive re-sectioning or removal of large portions of the lower urinary or bowel system components necessitating the rerouting of the urinary and/or bowel tracts to a new opening in abdomen of the patient that results in these patients no longer having a usable urinary or anal sphincter, at all. The new external orifice created in the abdomen is collectively known as a stoma. As a result of the ostomy surgery, which most often is a permanent procedure, the patient subsequently faces a lifetime of now draining their urine or fecal waste material into removable bags affixed to the stoma opening. There are approximately 750,000 ostomy patients currently in the US (with 2 million in our patent-covered markets) and approximately 60,000 new ostomy patients presenting into the US market each year (with another 160,000 patients presenting in our other patent covered markets). The new severe incontinence treatment technology being presented by Precision Medical Devices (PMD) that can be implanted in a 15 (to 20)-minute same day procedure, is designed, and expected to optimally treat the severer cases of both urinary and fecal incontinence sufferers, including those with serious gut disorders and ostomies as the device is essentially a new bionic sphincter. Notwithstanding the substantial cost savings for these patients, especially in the cases of ostomy patients where their ostomy bags may cost as much as $5,000 per year, the improvement of their quality-of- life (QoL) is incalculable.